• Publications
  • Influence
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
TLDR
STI571 is well tolerated and has significant antileukemic activity in patients with CML in whom treatment with interferon alfa had failed and demonstrates the potential for the development of anticancer drugs based on the specific molecular abnormality present in a human cancer. Expand
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
TLDR
The BCR-ABL tyrosine kinase inhibitor STI571 is well tolerated and has substantial activity in the blast crises of CML and in Ph-positive ALL. Expand
The biology of chronic myeloid leukemia.
TLDR
Although heterogeneous, CML is the best-characterized leukemia at a molecular level, and studies in recent years have helped to define further. Expand
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
TLDR
Imatinib induced high rates of cytogenetic and hematologic responses in patients with chronic-phase CML in whom previous interferon therapy had failed, and CML had not progressed to the accelerated or blast phases after a median follow-up of 18 months. Expand
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
TLDR
Ruxolitinib provided significant clinical benefits in patients with myel ofibrosis by reducing spleen size, ameliorating debilitating myelofibrosis-related symptoms, and improving overall survival. Expand
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
TLDR
Dasatinib induces hematologic and cytogenetic responses in patients with CML or Ph-positive ALL who cannot tolerate or are resistant to imatinib, which is effective in Philadelphia chromosome-positive leukemias but relapse occurs. Expand
Identification of targetable FGFR gene fusions in diverse cancers.
TLDR
Because of the combinatorial possibilities of FGFR family fusion to a variety of oligomerization partners, clinical sequencing efforts are poised to identify rare, targetable FGFR fusions across diverse cancer types. Expand
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
TLDR
Ponatinib was highly active in heavily pretreated patients with Ph-positive leukemias with resistance to tyrosine kinase inhibitors, including patients with the BCR-ABL T315I mutation, other mutations, or no mutations. Expand
Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing
TLDR
These studies establish NAB2-STAT6 as the defining driver mutation of SFT and provide an example of how neoplasia can be initiated by converting a transcriptional repressor of mitogenic pathways into an transcriptional activator. Expand
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.
TLDR
Comparison of samples from patients taken prior to and following STI571 failure suggested that expression and/or activation of LYN/HCK occurs during disease progression, and results suggest that acquired STi571 resistance may be associated with BCR-ABL independence and mediated in part through overexpression of other tyrosine kinases. Expand
...
1
2
3
4
5
...